Elanco Animal Health (ELAN)
(Delayed Data from NYSE)
$15.35 USD
+0.33 (2.20%)
Updated Sep 5, 2024 04:00 PM ET
3-Hold of 5 3
B Value B Growth F Momentum B VGM
Price, Consensus and EPS Surprise
ELAN 15.35 +0.33(2.20%)
Will ELAN be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ELAN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ELAN
Merck (MRK) Falls 10% in 3 Months: Should You Buy the Dip?
Merck (MRK) to Buy Curon's Bispecific Antibody Drug for $1.3B
ELAN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Elanco Animal Health (ELAN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Elanco Animal Health Incorporated (ELAN) Q2 Earnings and Revenues Top Estimates
RadNet (RDNT) Q2 Earnings Match Estimates
Other News for ELAN
50 stocks to invest during the bull steepening – Part 2
Elanco to Participate in Morgan Stanley 22nd Annual Global Healthcare Conference
Stocks with three weeks of improving technicals by Piper Sandler
Elanco Announces Credelio Quattro Moves to Final FDA Administrative Review
Tarsus Pharmaceuticals: Strong Execution In Eye Disease Treatment